Alyeska Investment Group, L.P. Longboard Pharmaceuticals, Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$17.0 - $27.03 $425,000 - $675,750	25,000 Added 13.31%	212,879 $5.75 Million
Q1 2024 May 15, 2024	BUY	$18.89 - $26.06 $3.55 Million - $4.9 Million	187,879 New	187,879 $4.06 Million
Q2 2022 Aug 15, 2022	SELL	$2.96 - $5.38 $104,831 - $190,538	-35,416 Reduced 56.67%	27,084 $84,000
Q3 2021 Nov 15, 2021	SELL	$8.65 - $11.36 $197,739 - $259,689	-22,860 Reduced 26.78%	62,500 $553,000
Q2 2021 Aug 16, 2021	SELL	$7.95 - $17.3 $315,138 - $685,772	-39,640 Reduced 31.71%	85,360 $778,000
Q1 2021 May 17, 2021	BUY	$16.0 - $16.89 $2 Million - $2.11 Million	125,000 New	125,000 $2.05 Million

126

34.9M

28.9K

13.9K

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.